Korro Bio Statistics
Share Statistics
Korro Bio has 9.37M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 9.37M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 2.26K |
| FTD / Avg. Volume | 1.66% |
Short Selling Information
The latest short interest is 261.96K, so 2.8% of the outstanding shares have been sold short.
| Short Interest | 261.96K |
| Short % of Shares Out | 2.8% |
| Short % of Float | 4.73% |
| Short Ratio (days to cover) | 1.57 |
Valuation Ratios
The PE ratio is -0.93 and the forward PE ratio is -6.45.
| PE Ratio | -0.93 |
| Forward PE | -6.45 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.44 |
| P/FCF Ratio | -1 |
| PEG Ratio | n/a |
Enterprise Valuation
Korro Bio Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 8.87, with a Debt / Equity ratio of 0.
| Current Ratio | 8.87 |
| Quick Ratio | 8.87 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.48% and return on capital (ROIC) is -41.63%.
| Return on Equity (ROE) | -0.48% |
| Return on Assets (ROA) | -0.37% |
| Return on Capital (ROIC) | -41.63% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -803.68K |
| Employee Count | 101 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 27.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -10.01% in the last 52 weeks. The beta is 0, so Korro Bio 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -10.01% |
| 50-Day Moving Average | 54.37 |
| 200-Day Moving Average | 51.19 |
| Relative Strength Index (RSI) | 46.11 |
| Average Volume (20 Days) | 136.21K |
Income Statement
In the last 12 months, Korro Bio had revenue of $0 and earned -$81.17M in profits. Earnings per share was $-53.09.
| Revenue | 0 |
| Gross Profit | -3.63M |
| Operating Income | -84.53M |
| Net Income | -81.17M |
| EBITDA | -80.90M |
| EBIT | - |
| Earnings Per Share (EPS) | -53.09 |
Balance Sheet
The company has $166.15M in cash and $33.21M in debt, giving a net cash position of $132.94M.
| Cash & Cash Equivalents | 166.15M |
| Total Debt | 33.21M |
| Net Cash | 132.94M |
| Retained Earnings | -183.00M |
| Total Assets | 243.54M |
| Working Capital | 139.17M |
Cash Flow
In the last 12 months, operating cash flow was -$67.28M and capital expenditures -$7.84M, giving a free cash flow of -$75.12M.
| Operating Cash Flow | -67.28M |
| Capital Expenditures | -7.84M |
| Free Cash Flow | -75.12M |
| FCF Per Share | -49.13 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
KRRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -114.2% |
| FCF Yield | -17.25% |
Analyst Forecast
The average price target for KRRO is $125, which is 168.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $125 |
| Price Target Difference | 168.9% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Nov 6, 2023. It was a backward split with a ratio of 1:50.
| Last Split Date | Nov 6, 2023 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | 1.94 |
| Piotroski F-Score | 2 |